Esophageal Trials
Select trial for more information
Area under investigation=true,Esophageal cancer,Gastric/GEJ cancer
Tumor
Advanced or metastatic gastric or GEJ adenocarcinoma expressing Claudin18.2, ≥2L
Trial Identifier
NCT06346392
Phase
III
Regimen
Sonesitatug vedotin (different doses); investigator's choice of chemotherapy
Claudin 18.2-positive advanced solid tumors (gastric/GEJ cancer, pancreatic adenocarcinoma, BTCs)
NCT06219941
II
Sonesitatug vedotin; sonesitatug vedotin + chemotherapy
HER2-expressing advanced/metastatic gastric/GEJ and esophageal adenocarcinoma
NCT04379596
Ib/II
Stage
Advanced
T-DXd ± (chemotherapy or durvalumab or pembrolizumab); T-DXd + chemotherapy + (durvalumab or pembrolizumab); T-DXd + volrustomig + chemotherapy; T-DXd + rilvegostomig + chemotherapy
fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.
Advanced or metastatic tumors (Cervical, HNSCC, pleural mesothelioma, and ESCC)
NCT06535607
Volrustomig monotherapy; volrustomig + chemotherapy
Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
NCT05702229
Volrustomig + (XELOX or FOLFOX); rilvegostomig + (XELOX or FOLFOX); volrustomig + sonesitatug vedotin + (5-FU or capecitabine); sonesitatug vedotin + 5-FU or capecitabine ± rilvegostomig
Locally advanced resectable GEJ adenocarcinoma
NCT07069712
Locally advanced resectable gastric, GEJ, or esophageal adenocarcinoma
Sonesitatug vedotin + rilvegostomig and 5-FU or capecitabine; T-DXd + rilvegostomig and 5-FU or capecitabine; rilvegostomig + FLOT chemotherapy
fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world. This study is sponsored by Daiichi Sankyo, Inc.
Locally advanced, unresectable esophageal squamous cell carcinoma
NCT04550260
Durvalumab + definitive cCRT; placebo + definitive cCRT
